Fields · Biotechnology
Alphabet's Isomorphic Labs closes a $5 billion raise, the biggest biotech cash infusion of the year, as AI-driven drug discovery draws capital even while late-stage results and regulatory decisions remain mixed.
The week was dominated by capital flows into AI-enabled drug discovery: Isomorphic Labs secured $5 billion led by Greenoaks and Sequoia with a 'significant' contribution from Alphabet, described as the two largest cash infusions in biotech this year, and Flagship committed £100 million to build 'AI-native platform companies' in the UK. Dealmaking by large pharma continued apace, with Lilly's $1.5 billion purchase of Calytrix marking its 15th announced acquisition of the year and J&J paying $2.2 billion for Ollin's vision-loss drug. Regulators sent contrasting signals, approving Roche's breast cancer pill but refusing Summit's PD-1/VEGF drug ivonescimab over its failure to extend survival.








































